CARD10 promotes the progression of renal cell carcinoma by regulating the NF‑κB signaling pathway

Peng,Longfei; He,Ke; Cao,Zhangjun; Bi,Liangkuan; Yu,Dexin; Wang,Qi; Wang,Jinyou

doi:10.3892/mmr.2019.10840

CARD10 promotes the progression of renal cell carcinoma by regulating the NF‑κB signaling pathway

Authors:
- Longfei Peng
- Ke He
- Zhangjun Cao
- Liangkuan Bi
- Dexin Yu
- Qi Wang
- Jinyou Wang
View Affiliations

Affiliations: Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, P.R. China
Published online on: November 21, 2019 https://doi.org/10.3892/mmr.2019.10840
Pages: 329-337
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that the expression of CARD10 is closely associated with the occurrence of tumors, and its role is mainly to promote tumor progression by activating the transcription factor NF‑κB. However, the signaling pathway in renal cancer remains unclear. The objective of the present study was to investigate the ability of caspase recruitment domain 10 (CARD10) to regulate the NF‑κB signaling pathway and promote the progression of renal cell carcinoma (RCC). Expression of CARD10 in ACHN, 786‑O and HK‑2 cells was evaluated via western blot analysis, as was the epidermal growth factor (EGF)‑induced activation of NF‑κB signaling pathway‑related proteins in cells. The expression of CARD10 was inhibited by CARD10 short hairpin RNA transfection. Cell cycle analysis and MTT assays were used to evaluate cell proliferation. Cell apoptosis was analyzed via flow cytometry. The invasion of renal cell lines was detected via Transwell cell migration and invasion assays in vitro. The results showed that CARD10 expression was significantly higher in RCC cells than in normal renal tubular epithelial cells. CARD10 silencing inhibited the proliferation, invasion and migration of RCC cells. EGF stimulation upregulated the activation of the NF‑κB pathway in RCC cells. Inhibition of CARD10 expression inhibited NF‑κB activation in RCC cells. Taken together, these data suggested that CARD10 promotes the progression of renal cell carcinoma by regulating the NF‑κB signaling pathway. Thus, this indicated that CARD10 may be a novel therapeutic target in RCC.

View Figures

View References

1	Capitanio U and Montorsi F: Renal cancer. Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
2	Kuusk T, Grivas N, de Bruijn R and Bex A: The current management of renal cell carcinoma. Minerva Med. 108:357–369. 2017.PubMed/NCBI
3	Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
4	Zotti T, Polvere I, Voccola S, Vito P and Stilo R: CARD14/CARMA2 signaling and its role in inflammatory skin disorders. Front Immunol. 9:21672018. View Article : Google Scholar : PubMed/NCBI
5	Scudiero I, Vito P and Stilo R: The three CARMA sisters: So different, so similar: A portrait of the three CARMA proteins and their involvement in human disorders. J Cell Physiol. 229:990–997. 2014. View Article : Google Scholar : PubMed/NCBI
6	Stilo R, Liguoro D, Di Jeso B, Formisano S, Consiglio E, Leonardi A and Vito P: Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator. J Biol Chem. 279:34323–34331. 2004. View Article : Google Scholar : PubMed/NCBI
7	Blonska M and Lin X: NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res. 21:55–70. 2011. View Article : Google Scholar : PubMed/NCBI
8	Jiang C and Lin X: Regulation of NF-κB by the CARD proteins. Immunol Rev. 246:141–153. 2012. View Article : Google Scholar : PubMed/NCBI
9	Juilland M and Thome M: Holding all the CARDs: How MALT1 controls CARMA/CARD-dependent signaling. Front Immunol. 9:19272018. View Article : Google Scholar : PubMed/NCBI
10	Wang L, Qian L, Li X and Yan J: MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. Mol Med Rep. 10:473–478. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chang YW, Chiu CF, Lee KY, Hong CC, Wang YY, Cheng CC, Jan YH, Huang MS, Hsiao M, Ma JT and Su JL: CARMA3 represses metastasis suppressor NME2 to promote lung cancer stemness and metastasis. Am J Respir Crit Care Med. 192:64–75. 2015. View Article : Google Scholar : PubMed/NCBI
12	Du S, Jia L, Zhang Y, Fang L, Zhang X and Fan Y: CARMA3 is upregulated in human pancreatic carcinoma, and its depletion inhibits tumor proliferation, migration, and invasion. Tumour Biol. 35:5965–5970. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, et al: The CARMA3-Bcl10-MALT1 signalosome drives NFκB activation and promotes aggressiveness in angiotensin II receptor-positive breast cancer. Cancer Res. 78:1225–1240. 2018. View Article : Google Scholar : PubMed/NCBI
14	Xie C, Han Y, Fu L, Li Q, Qiu X and Wang E: Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer. Tumour Biol. 35:7957–7964. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wu GL, Yuan JL, Huang XD, Rong JF, Zhang LX, Liu YP and Wang FL: Evaluating the expression of CARMA3 as a prognostic tumor marker in renal cell carcinoma. Tumour Biol. 34:3431–3435. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zhang X, Liu X, Jing Z, Bi J, Li Z, Liu X, Li J, Li Z, Zhang Z and Kong C: The circINTS4/miR-146b/CARMA3 axis promotes tumorigenesis in bladder cancer. Cancer Gene Ther. 2019.(Epub ahead of print). View Article : Google Scholar
17	Man X, He J, Kong C, Zhu Y and Zhang Z: Clinical significance and biological roles of CARMA3 in human bladder carcinoma. Tumour Biol. 35:4131–4136. 2014. View Article : Google Scholar : PubMed/NCBI
18	Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z and Huang S: Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene. 27:1273–1280. 2008. View Article : Google Scholar : PubMed/NCBI
19	Wang D, You Y, Lin PC, Xue L, Morris SW, Zeng H, Wen R and Lin X: Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors. Proc Natl Acad Sci USA. 104:145–150. 2007. View Article : Google Scholar : PubMed/NCBI
20	Zhang S, Zhang C, Liu W, Zheng W, Zhang Y, Wang S, Huang D, Liu X and Bai Z: MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3. Int J Oncol. 47:1351–1360. 2015. View Article : Google Scholar : PubMed/NCBI
21	Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC and Karin M: Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 293:1495–1499. 2001. View Article : Google Scholar : PubMed/NCBI
22	Zhang S and Lin X: CARMA3: Scaffold protein involved in NF-κB signaling. Front Immunol. 10:1762019. View Article : Google Scholar : PubMed/NCBI
23	Mitchell S, Vargas J and Hoffmann A: Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 8:227–241. 2016. View Article : Google Scholar : PubMed/NCBI
24	Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-kB in development and progression of human cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
25	Cildir G, Low KC and Tergaonkar V: Noncanonical NF-κB signaling in health and disease. Trends Mol Med. 22:414–429. 2016. View Article : Google Scholar : PubMed/NCBI
26	DiDonato JA, Mercurio F and Karin M: NF-κB and the link between inflammation and cancer. Immunol Rev. 246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
27	Xia Y, Shen S and Verma IM: NF-κB, an active player in human cancers. Cancer Immunol Res. 2:823–830. 2014. View Article : Google Scholar : PubMed/NCBI
28	McAuley JR, Freeman TJ, Ekambaram P, Lucas PC and McAllister-Lucas LM: CARMA3 is a critical mediator of G protein-coupled receptor and receptor tyrosine kinase-driven solid tumor pathogenesis. Front Immunol. 9:18872018. View Article : Google Scholar : PubMed/NCBI
29	Jiang C and Lin X: Analysis of epidermal growth factor-induced NF-κB signaling. Methods Mol Biol. 1280:75–102. 2015. View Article : Google Scholar : PubMed/NCBI
30	Pan D and Lin X: Epithelial growth factor receptor-activated nuclear factor κB signaling and its role in epithelial growth factor receptor-associated tumors. Cancer J. 19:461–467. 2013. View Article : Google Scholar : PubMed/NCBI
31	Pan D, Zhu Y, Zhou Z, Wang T, You H, Jiang C and Lin X: The CBM complex underwrites NF-κB activation to promote HER2-associated tumor malignancy. Mol Cancer Res. 14:93–102. 2016. View Article : Google Scholar : PubMed/NCBI
32	Jiang C, Zhou Z, Quan Y, Zhang S, Wang T, Zhao X, Morrison C, Heise MT, He W, Miller MS and Lin X: CARMA3 is a host factor regulating the balance of inflammatory and antiviral responses against viral infection. Cell Rep. 14:2389–2401. 2016. View Article : Google Scholar : PubMed/NCBI
33	Chen R, Jin G and McIntyre TM: The soluble protease ADAMDEC1 released from activated platelets hydrolyzes platelet membrane pro-epidermal growth factor (EGF) to active high-molecular-weight EGF. J Biol Chem. 292:10112–10122. 2017. View Article : Google Scholar : PubMed/NCBI
34	Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE III and Ganju RK: Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol. 9:906–919. 2015. View Article : Google Scholar : PubMed/NCBI
35	Li Y, Lin Z, Chen B, Chen S, Jiang Z, Zhou T, Hou Z and Wang Y: Ezrin/NF-kB activation regulates epithelial-mesenchymal transition induced by EGF and promotes metastasis of colorectal cancer. Biomed Pharmacother. 92:140–148. 2017. View Article : Google Scholar : PubMed/NCBI
36	Wu W, Jaspers I, Zhang W, Graves LM and Samet JM: Role of Ras in metal-induced EGF receptor signaling and NF-kappaB activation in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 282:L1040–L1048. 2002. View Article : Google Scholar : PubMed/NCBI
37	Liptay S, Weber CK, Ludwig L, Wagner M, Adler G and Schmid RM: Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer. 105:735–746. 2003. View Article : Google Scholar : PubMed/NCBI
38	Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, Lang J, Hung MC and Lin X: CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression. Cancer Res. 71:2183–2192. 2011. View Article : Google Scholar : PubMed/NCBI